The Medical Letter - 2018
Search or Select Article Below and Click to Purchase
Year:    Publication:      2018 Annual Index: U.S. English | Canadian English
January 1, 2018 (Issue 1537)  
January 15, 2018 (Issue 1538)  
January 29, 2018 (Issue 1539)  
February 12, 2018 (Issue 1540)  
February 26, 2018 (Issue 1541)  
March 12, 2018 (Issue 1542)  
March 26, 2018 (Issue 1543)  
April 9, 2018 (Issue 1544)  
April 23, 2018 (Issue 1545)  
May 7, 2018 (Issue 1546)  
May 21, 2018 (Issue 1547)  
June 4, 2018 (Issue 1548)  
June 18, 2018 (Issue 1549)  
July 2, 2018 (Issue 1550)  
July 16, 2018 (Issue 1551)  
  • Lofexidine (Lucemyra) for Opioid Withdrawal
    The FDA has approved lofexidine (Lucemyra – US WorldMeds/Salix), a centrally acting alpha2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid...
  • Two New Drugs for Glaucoma
    The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod (Vyzulta –...
  • Baricitinib (Olumiant) for Rheumatoid Arthritis
    The FDA has approved the Janus kinase (JAK) inhibitor baricitinib (Olumiant – Lilly) for oral treatment of adults with moderately to severely active rheumatoid arthritis (RA) that has...
  • Firvanq - Vancomycin Oral Solution
    The FDA has approved vancomycin oral solution (Firvanq – Cutis Pharma) for treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus...
  • Correction: Abuse-Deterrent Opioids
    In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95), the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a...
  • Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)
    The FDA has approved axicabtagene ciloleucel (Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy....
  • Apalutamide (Erleada) for Prostate Cancer (online only)
    Apalutamide (Erleada – Janssen) has received accelerated approval from the FDA for treatment of nonmetastatic castration-resistant prostate cancer. It is the first drug to be approved in...
July 30, 2018 (Issue 1552)  
August 13, 2018 (Issue 1553)  
  • Sunscreens
    Excessive exposure to ultraviolet (UV) radiation is associated with sunburn, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but some questions remain about...
  • Biktarvy - Another INSTI-Based Combination for HIV
    The FDA has approved Biktarvy (Gilead), a once-daily, fixed-dose combination of bictegravir, a new integrase strand transfer inhibitor (INSTI), and the nucleoside reverse transcriptase...
  • Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
    The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin (Otiprio – Otonomy) for single-dose treatment of acute otitis externa...
  • In Brief: More Fluoroquinolone Warnings
    The FDA has required changes in the labeling of all systemic fluoroquinolone antibiotics to strengthen warnings about the risk of severe hypoglycemia and mental health effects associated with their...
August 27, 2018 (Issue 1554)  
September 10, 2018 (Issue 1555)  
September 24, 2018 (Issue 1556)  
October 8, 2018 (Issue 1557)  
  • Choice of Contraceptives
    Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also...
October 22, 2018 (Issue 1558)  
  • Influenza Vaccine for 2018-2019
    Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in...
  • Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis
    The FDA has approved the fixed-dose combination of tezacaftor and ivacaftor (Symdeko – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who are homozygous...
  • OTC Brimonidine (Lumify) for Ocular Redness
    The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for...
November 5, 2018 (Issue 1559)  
November 19, 2018 (Issue 1560)  
December 3, 2018 (Issue 1561)  
December 17, 2018 (Issue 1562)